Video

Dr. Vorobiof on Financial Toxicity in Oncology

Daniel A. Vorobiof, MD, discusses financial toxicity in oncology.

Daniel A. Vorobiof, MD, chief medical director of Belong.Life, discusses financial toxicity in oncology.

Financial toxicity is an ongoing problem in the oncology space that has not been properly addressed to date, Vorobiof says.

In the United States, cancer is among the most expensive diseases to treat, along with heart disease, Vorobiof says. Moreover, financial toxicity is a global problem and cancer-related treatment expenses are continuing to rise.

Although financial toxicity may affect all patients differently, some health care professionals have been detached from the widespread burden financial toxicity can place on a patient with cancer, concludes Vorobiof.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
R. Lor Randall, MD, FACS
Joshua Richter, MD of Tisch Cancer Institute
Guenther Koehne, MD, deputy director and chief of Stem Cell Transplantation, Hematologic Oncology and Benign Hematology at Miami Cancer Institute, Baptist Health South Florida
Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center
Bradley McGregor, MD
Katherine L. Nathanson, MD
Daniel J. DeAngelo, MD, PhD, chief of the Division of Leukemia and an institute physician at Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School
Julie M. Vose, MD, MBA
6369343864112
Matthew Wagar, MD of the University of Wisconsin School of Medicine and Public Health